Podcasts

2017



DOTLogo2017 Small Molecule Ubiquitin Protease (USP7) Inhibitors with Immune Cell Based Anti-Tumor Activity Superior to that of Biologicals
with Tauseef R. Butt, Ph.D., President and CEO, Progenra, Inc.
NEW!



DOTLogo2017 Targeted Platform for RNA Therapeutics
with Dan Peer, Ph.D., Director, Laboratory of Precision NanoMedicine, Tel Aviv University
NEW!



DOTLogo2017 PROTACs: The Chemical Equivalent of CRISPR
with Craig M. Crews, Ph.D., Lewis B. Cullman Professor of Molecular, Cellular, and Developmental Biology; Professor, Chemistry & Pharmacology, Yale University
NEW!



2016



DOT_Logo_2016 Advances and Challenges in the Discovery and Development of Histone Demethylase Inhibitors
with Dr. Christopher Schofield, Head of Organic Chemistry in the Chemistry Research Laboratory at the University of Oxford



2015 Podcasts



DOTLogo2016 Targeting The Unfolded Protein Response - A New Avenue for Drug Discovery
with Claudio Hetz, Ph.D., Professor, Institute of Biomedical Sciences, University of Chile; Principal Investigator, Laboratory of Cellular Stress and Biomedicine, Adjunct Professor, School of Public Health, Harvard University



DOTLogo2016 Histone Methyltransferase and Demethylase Inhibitor Discovery: Current Challenges, Novel Tools and Emerging Targets
with Trevor Perrior, Ph.D., Director, Research, Domainex Limited and Gregg Siegal, Ph.D., CEO, ZoBio



DOTLogo2016 Targeting DUBs: Drug Discovery Challenges, Enabling Technologies and Translating into the Clinic
with Xavier Jacq, Ph.D., Head of Biology, MISSION Therapeutics



2014 Podcasts



DOTLogo Development of Histone Demethylase Inhibitors for Oncological and Neurodegenerative Disease
with Tamara Maes, Ph.D., Co-Founder, Vice President & CSO, Oryzon Genomics



DOTLogo Opportunities and Challenges with Developing Small Molecule Inhibtors Targeting the Ubiquitin Proteasome System (UPS)
with Benedikt Kessler, Ph.D., University Research Lecturer, Ubiquitin Proteolysis Group, Target Discovery Institute, Nuffield Department of Medicine, University of Oxford



DOTLogo Targeting BET Bromodomains in Cancer: In Vivo Efficacy & Toxicity, Challenges and Outlook
with Jialiang Wang, Ph.D., Assistant Professor, Neurological Surgery, Vanderbilt University